

STELIS BIOPHARMA MALAYSIA SDN BHD
BALANCE SHEET AS AT MARCH 31, 2023

	Note No.	Amount in MYR 31-Mar-23	Amount in MYR 31-Mar-22
A ASSETS			
I Current assets			
(a) Financial assets			
(i) Cash and cash equivalents	1	4,702	4,197
(ii) Other financial assets	2	5,413,369	5,191,521
Total current assets		5,418,071	5,195,718
TOTAL ASSETS		5,418,071	5,195,718
B EQUITY AND LIABILITIES			
I Equity			
(a) Equity share capital	3	13,282,094	13,282,094
(b) Other equity	4	(7,865,137)	(8,110,831)
Total Equity		5,416,957	5,171,263
II Liabilities			
1 Current liabilities			
(a) Financial liabilities			
(i) Trade payables	5	1,113	17,954
(b) Other current liabilities	6	1	6,501
Total current liabilities		1,113	24,455
TOTAL EQUITY AND LIABILITIES		5,418,071	5,195,718

STELIS BIOPHARMA MALAYSIA SDN BHD
STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2023

		Amount in MYR	Amount in MYR
Particulars	Note No.	31-Mar-23	31-Mar-22
1 Revenue from operations		-	-
2 Other Income	7	263,728	102,138
3 Total Revenue (1+2)		<u>263,728</u>	<u>102,138</u>
4 Expenses			
(a) Finance costs	8	33	42
(b) Other expenses	9	18,001	26,825
Total expenses		<u>18,034</u>	<u>26,867</u>
5 Profit / (Loss) before exceptional items and taxes (3-4)		<u>245,694</u>	<u>75,271</u>
6 Exceptional Item		-	-
7 Profit / (Loss) before taxes (5+6)		<u>245,694</u>	<u>75,271</u>
8 Tax Expense:			
(1) Current tax		-	-
(2) Deferred tax		-	-
Total tax expenses		<u>-</u>	<u>-</u>
9 Profit / (Loss) for the year after tax		<u>245,694</u>	<u>75,271</u>

STELIS BIOPHARMA MALAYSIA SDN BHD
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED MARCH 31, 2023

(A) Equity share capital

Particulars	Amount in MYR
Balance as at March 31, 2022	13,282,094
Changes in equity share capital during the year	-
Balance as at March 31, 2023	13,282,094

(B) Other equity

Amount in MYR

Particulars	Securities Premium	Reserves and surplus	Items of other comprehensive income	Total
		Retained earnings	Re -measurement of the defined benefit liabilities / (assets)	
Balance as at March 31, 2022	-	(8,110,831)	-	(8,110,831)
Profit/loss for the year	-	245,694	-	245,694
Balance as at March 31, 2023	-	(7,865,137)	-	(7,865,137)

STELIS BIOPHARMA MALAYSIA SDN BHD

Notes forming part of financial statement

Note

No.

1	Cash and cash equivalents	Amount in MYR	
	Particulars	31-Mar-23	31-Mar-22
	Balances with banks:		
	In current accounts	4,702	4,197
	Total	4,702	4,197
2	Other financial assets	Amount in MYR	
	Particulars	31-Mar-23	31-Mar-22
	Advances to related parties	5,413,369	5,191,521
	Total	5,413,369	5,191,521
3	Share capital	Amount in MYR	
	Particulars	31-Mar-23	31-Mar-22
	Issued, subscribed and fully paid-up		
	Equity share capital	13,282,094	13,282,094
	Total	13,282,094	13,282,094
4	Reserves and surplus	Amount in MYR	
	Particulars	31-Mar-23	31-Mar-22
	Surplus in statement of profit and loss		
	Opening balance	(8,110,831)	(8,186,102)
	Add: Profit / (Loss) for the year	245,694	75,271
	Closing balance	(7,865,137)	(8,110,831)
	Total	(7,865,137)	(8,110,831)
5	Trade payables	Amount in MYR	
	Particulars	31-Mar-23	31-Mar-22
	Trade payable	1,113	17,954
	Total	1,113	17,954
6	Other current liabilities	Amount in MYR	
	Particulars	31-Mar-23	31-Mar-22
	Provision for expenses	1	6,501
	Total	1	6,501

STELIS BIOPHARMA MALAYSIA SDN BHD
Notes forming part of financial statement

Note

No.

7 Other Income **Amount in MYR**

Particulars	31-Mar-23	31-Mar-22
Exchange fluctuation gain	230,677	102,138
Interest Income	32	-
Sundry Creditors written off	33,020	
Total	263,728	102,138

8 Finance cost **Amount in MYR**

Particulars	31-Mar-23	31-Mar-22
Bank charges	33	42
Total	33	42

9 Other expenses **Amount in MYR**

Particulars	31-Mar-23	31-Mar-22
Rates & Taxes	37	133
Printing & Stationery	-	25,100
Conveyance & Travelling	-	50
Director sitting fees	-	-
Net loss on foreign currency transactions	-	-
Professional fees	16,464	42
Payment to Auditors - For Statutory Audit	1,500	1,500
Total	18,001	26,825